| Literature DB >> 31313072 |
Lauren E Heusinkveld1,2, Shamik Majumdar1, Ji-Liang Gao1, David H McDermott1, Philip M Murphy3.
Abstract
WHIM syndrome is a rare combined primary immunodeficiency disease named by acronym for the diagnostic tetrad of warts, hypogammaglobulinemia, infections, and myelokathexis. Myelokathexis is a unique form of non-cyclic severe congenital neutropenia caused by accumulation of mature and degenerating neutrophils in the bone marrow; monocytopenia and lymphopenia, especially B lymphopenia, also commonly occur. WHIM syndrome is usually caused by autosomal dominant mutations in the G protein-coupled chemokine receptor CXCR4 that impair desensitization, resulting in enhanced and prolonged G protein- and β-arrestin-dependent responses. Accordingly, CXCR4 antagonists have shown promise as mechanism-based treatments in phase 1 clinical trials. This review is based on analysis of all 105 published cases of WHIM syndrome and covers current concepts, recent advances, unresolved enigmas and controversies, and promising future research directions.Entities:
Keywords: CXCL12; CXCR2; CXCR4; Chemokine; human papillomavirus; myelokathexis; plerixafor
Mesh:
Year: 2019 PMID: 31313072 PMCID: PMC6698215 DOI: 10.1007/s10875-019-00665-w
Source DB: PubMed Journal: J Clin Immunol ISSN: 0271-9142 Impact factor: 8.317